Pyroptosis

A form of lytic programmed cell death executed by gasdermin-family pore-forming proteins, characterized by plasma-membrane rupture, concomitant release of mature IL-1β and IL-18, and release of damage-associated molecular patterns (DAMPs). Pyroptosis is mechanistically distinct from apoptosis (non-lytic, immunologically silent), necroptosis (RIPK3-MLKL-mediated; TNF-driven), and ferroptosis (lipid-peroxidation-driven). The term was coined by Cookson and Brennan ~2001 to describe caspase-1-dependent macrophage death during Salmonella infection unsourced — original Trends Microbiol 2001 DOI not confirmed in archive; formal NCCD nomenclature consolidated in Galluzzi 2018 ¹.

In aging biology, pyroptosis is a major effector mechanism downstream of nlrp3-inflammasome activation and a key amplifier of inflammaging. Repeated pyroptosis of non-renewable cell populations (cardiomyocytes, vascular endothelium) constitutes an irreversible cell-pool drain.

Mechanism

Canonical pathway (inflammasome-dependent)

1. Sensing: Pattern recognition receptors detect PAMPs (pathogen-associated) or DAMPs (danger signals, sterile inflammation). The NLRP3 inflammasome responds to a broad range of sterile DAMPs relevant to aging — cholesterol crystals, urate, ATP, amyloid-β, lipid peroxidation products.
2. ASC speck formation: asc (apoptosis-associated speck-like protein containing a CARD) oligomerizes into a single ~1 µm “speck” per cell, bridging the sensor (e.g., nlrp3) to the effector caspase.
3. Caspase-1 activation: Pro-caspase-1 is recruited to the ASC speck and autocatalytically processed to active caspase-1 (p20/p10 heterotetramer).
4. GSDMD cleavage: Active caspase-1 cleaves gsdmd between its N-terminal pore-forming domain (GSDMD-N) and C-terminal autoinhibitory domain (GSDMD-C). Released GSDMD-N translocates to the inner leaflet of the plasma membrane.
5. Pore formation: GSDMD-N oligomerizes into a ring-shaped pore. Two source-chains give different stoichiometries: Galluzzi 2018 (NCCD nomenclature review) reports ~10–14 nm inner diameter, 16 symmetric protomers ¹; the more recent primary cryo-EM literature (Liu 2016 / Pan 2018, summarized on the verified gsdmd page) reports ~18 nm inner diameter, ~27 monomers. The 27-mer / 18-nm value is the structurally direct measurement and is the current best estimate; the Galluzzi 2018 figure is preserved here for traceability of the older review-derived number. The pore drives K⁺ efflux, water influx, and osmotic swelling.
6. IL-1β / IL-18 maturation and release: Caspase-1 also cleaves pro-IL-1β and pro-IL-18 to their mature forms; these bioactive cytokines exit through GSDMD pores before membrane rupture and are additionally released in bulk upon lysis.
7. Membrane lysis: Sustained osmotic pressure exceeds membrane capacity → plasma membrane rupture → release of cytoplasmic contents including HMGB1, ATP, and other DAMPs ².

Inflammasome platforms that feed the canonical pathway: NLRP3, NLRC4 (flagellin/rod proteins), AIM2 (cytosolic dsDNA), pyrin (Rho-GTPase disruption). Each recruits ASC (or directly activates caspase-1 in the case of NLRC4) and converges on the same GSDMD executioner step.

Non-canonical pathway (inflammasome-independent)

In mice, cytosolic LPS is sensed directly by caspase-11 (a murine-specific protein); in humans, the orthologues caspase-4 and caspase-5 perform the equivalent function. These inflammatory caspases are activated by direct LPS binding without requiring an ASC speck or caspase-1. They cleave GSDMD directly, triggering the same pore-formation and osmotic lysis program ³.

Key distinction: the non-canonical pathway does not mature IL-1β or IL-18 directly (caspase-4/5/11 do not process these cytokines); instead, GSDMD-mediated K⁺ efflux subsequently activates NLRP3, leading to secondary caspase-1 activation and cytokine maturation.

Feature	Canonical	Non-canonical
Sensor	NLRP3, NLRC4, AIM2, pyrin	Caspase-4/5 (human) / Caspase-11 (mouse)
Adaptor	ASC speck	None (direct LPS binding)
Caspase	Caspase-1	Caspase-4/5/11
IL-1β/IL-18 maturation	Direct (caspase-1)	Indirect (secondary NLRP3)
GSDMD cleavage	Yes	Yes

Executioner step: GSDMD-N pore

GSDMD-N has intrinsic affinity for phosphatidylserine and phosphatidylinositol (inner leaflet lipids); it does not bind the outer leaflet, providing cell-autonomous selectivity — bystander cells expressing GSDMD are not killed by extracellular GSDMD-N fragments ⁴. The pore is permeable to molecules up to ~4 kDa needs-replication (permeability threshold from Shi 2015, not_oa — unverified against local PDF), enabling IL-1β (~17 kDa) to exit only at low concentrations before full lysis; the bulk of IL-1β release requires membrane rupture.

Distinction from related death modes

Feature	Pyroptosis	Apoptosis	Necroptosis	Ferroptosis
Membrane integrity	Lost (lytic)	Preserved until phagocytosis	Lost (lytic)	Lost (lytic)
Key executioner	GSDMD	Caspase-3/7	MLKL	GPX4 loss → lipid ROS
Inflammation	Strong (IL-1β, IL-18, DAMPs)	Minimal (immunologically silent)	Moderate (DAMPs, no IL-1β)	Moderate (lipid aldehydes)
Morphology	Cell swelling, bubble-bleb	Cell shrinkage, apoptotic bodies	Cell swelling	Shrunken mitochondria
Key upstream trigger	Inflammasome or cytosolic LPS	Intrinsic/extrinsic apoptosis signals	TNF-R / RIPK3 activation	Oxidized lipid accumulation
Caspase dependence	Yes (caspase-1 or -4/5/11)	Yes (caspase-3/7)	No	No

Formal NCCD 2018 nomenclature: pyroptosis is defined as “a type of RCD that critically depends on the formation of plasma membrane pores by members of the gasdermin protein family, often (but not always) as a consequence of inflammatory caspase activation” ¹. This distinguishes it from secondary necrosis (the late stage of un-cleared apoptotic cells), which is not programmed. The NCCD also discourages the use of the alternative term “pyronecrosis.”

Aging relevance

NLRP3-driven pyroptosis as an inflammaging amplifier

The NLRP3 inflammasome is chronically activated in aged tissues by sterile DAMPs that accumulate with age: mitochondrial DNA (released by dysfunctional mitochondria), cholesterol crystals, urate crystals, and ox-LDL ⁵. Downstream caspase-1-mediated pyroptosis amplifies the inflammaging cycle: lytic cell death releases more DAMPs, which re-activate NLRP3 in neighboring cells. This feed-forward loop is increasingly recognized as central to inflammaging needs-human-replication — most mechanistic evidence from aged mouse macrophages and in-vitro aged human cells.

Cell populations affected by age-related pyroptosis

• Macrophages / monocytes: Elevated NLRP3-caspase-1 activity in aged macrophages (mouse and human); promotes IL-1β-driven systemic inflammation.
• Vascular endothelial cells: Pyroptosis of endothelial cells contributes to atherosclerotic plaque vulnerability and endothelial barrier breakdown. Non-renewable pool in adults.
• Cardiomyocytes: NLRP3-pyroptosis in cardiomyocytes reported in aged and failing hearts. Cardiomyocytes are largely post-mitotic; pyroptotic loss is not compensated. needs-human-replication
• Microglia: Pyroptosis of activated microglia contributes to neuroinflammation; seen in Alzheimer’s-disease-model mice and in human AD brain tissue (caspase-1 activation, GSDMD cleavage). contradictory-evidence — causal vs correlative role disputed.
• Adipocytes: NLRP3 activation in visceral adipose tissue drives pyroptotic adipocyte death; associated with metabolic inflammaging.

Pyroptosis vs cellular senescence — mechanistic comparison

Senescent cells (SASP) and pyroptotic cells both release IL-1β and IL-18, which has caused confusion. Key distinctions:

Feature	Pyroptosis	Senescent SASP
Cell fate	Death (lytic)	Cell survives (non-lytic)
IL-1β release mechanism	Caspase-1 cleavage + GSDMD pore / lysis	NF-κB transcription + unconventional secretion
Sustained output	One-time burst at death	Chronic, persists for years
GSDMD role	Required executioner	Not required for SASP
Reversible?	No	Yes (senolytics eliminate cell)

Senescent cells can also undergo caspase-1/GSDMD-dependent pyroptosis if NLRP3 activates — this “senoptosis” has been proposed as a convergence mechanism but is mechanistically distinct from classical SASP. needs-replication

Therapeutic targeting

Upstream: inflammasome inhibitors

• MCC950 (CMPD-4) — potent, selective NLRP3 inhibitor (IC₅₀ ~7.5 nM); blocks ASC speck formation; reduces IL-1β secretion and pyroptosis in multiple disease models. Preclinical; no approved drug yet ⁶.
• OLT1177 (dapansutrile) — orally available NLRP3 inhibitor; Phase 2 trials for gout/heart failure (not aging per se).

Caspase-1 inhibitors (upstream of GSDMD)

• VX-740 (pralnacasan) and VX-765 (belnacasan) — caspase-1 inhibitors; tested in Phase 2 for rheumatoid arthritis; disappointing efficacy, possibly because cytokine transcription (NF-κB) continued even with caspase-1 block. Clinical development discontinued.

Direct GSDMD inhibitors

• Disulfiram — approved FDA drug (alcohol aversion); blocks GSDMD-N pore formation via covalent modification of Cys191 (human) or Cys192 (mouse) of GSDMD-N ⁶. Repurposing context: COVID-19 hyperinflammation trials; aging application preclinical. needs-human-replication
• Sulforaphane analogues — reported to inhibit GSDMD pore formation; preclinical only. needs-human-replication

Downstream cytokine blockade

• Canakinumab (anti-IL-1β monoclonal antibody, Novartis) — FDA-approved for cryopyrin-associated periodic syndromes; the CANTOS trial (n=10,061 post-MI patients) showed a 15% reduction in recurrent MACE (nonfatal MI, nonfatal stroke, or cardiovascular death) at the 150-mg dose (HR 0.85, 95% CI 0.74–0.98, p=0.021) ⁷; the 300-mg dose also met its pre-specified significance threshold (HR 0.86, 95% CI 0.75–0.99, p=0.031). Supports the IL-1β pathway as clinically relevant in atherosclerotic inflammaging. High cost limits wide use; no aging-specific trial yet.
• Anakinra (IL-1 receptor antagonist) — shorter half-life biologic; approved for RA and CAPS; used off-label in cytokine storms.
• Anti-IL-18 (tadekinig alfa) — recombinant IL-18 binding protein; Phase 2/3 in macrophage activation syndrome.

Extrapolation table

Dimension	Status
GSDMD/caspase-1 mechanism conserved in humans?	yes
NLRP3 inflammasome conserved in humans?	yes
Pyroptosis in aged human tissues demonstrated?	partial — macrophage/endothelial data; cardiomyocyte/microglial data mostly mouse
Therapeutic modulation tested in humans?	yes (IL-1β blockade — CANTOS); GSDMD direct inhibition: no

Limitations and gaps

• Direct demonstration of GSDMD-dependent pyroptosis in aged human cardiomyocytes or microglia in vivo is lacking; most evidence is from mouse models or cell lines. needs-human-replication
• Whether pyroptosis rate increases measurably with chronological age in humans (vs. in disease contexts) has not been quantified with robust biomarkers. no-mechanism
• GSDMD cleavage fragments are detectable in plasma but are not yet validated as reliable aging biomarkers. needs-replication
• Whether disulfiram’s GSDMD-blocking effect at clinically safe doses (used for alcoholism) is sufficient to meaningfully reduce inflammaging is unknown. dose-response-unclear
• Caspase-4/5 (non-canonical) contributions to human inflammaging are understudied relative to caspase-1/NLRP3. needs-human-replication

Cross-references

• caspase-1 — canonical executioner caspase
• gsdmd — pore-forming executioner protein
• asc — adaptor bridging sensor to caspase-1
• nlrp3-inflammasome — major upstream platform
• il-1b — key pro-inflammatory cytokine matured and released
• il-18 — IFN-γ-inducing cytokine co-released
• canakinumab — downstream IL-1β blockade (clinical)
• apoptosis — non-lytic programmed death (contrast)
• cellular-senescence — SASP overlap; mechanistically distinct
• chronic-inflammation — hallmark driven by pyroptosis feed-forward
• nlrp3 — sensor protein seeding in same batch

Footnotes

Footnotes

1. doi:10.1038/s41418-017-0012-4 · Galluzzi L et al. · Cell Death Differ 2018 · review · NCCD 2018 nomenclature; formally defines pyroptosis as gasdermin-dependent lytic cell death · local PDF available ↩ ↩² ↩³

2. doi:10.1111/j.1462-5822.2006.00751.x · Fink SL, Cookson BT · Cell Microbiol 2006 · in-vitro · Caspase-1-dependent pore formation leads to osmotic lysis; distinguishes pyroptosis from apoptosis morphologically · archive status: failed (bronze OA, download attempted 2026-05-06; no downloadable URL found) no-fulltext-access ↩

3. doi:10.1038/nature15541 · Kayagaki N et al. · Nature 2015 · in-vitro + in-vivo · Demonstrates caspase-11 cleaves GSDMD for non-canonical pyroptosis independent of ASC speck · not-oa ↩

4. doi:10.1038/nature15514 · Shi J et al. · Nature 2015 · in-vitro + in-vivo · Identifies GSDMD as the direct caspase-1/11 substrate whose N-terminal fragment executes pyroptosis · n=multiple cell lines + mouse models · not-oa · note: original pore-size attribution (~10–20 nm) superseded; Galluzzi 2018 (verified, local PDF) cites structural characterization giving ~10–14 nm (16 protomers) ↩

5. doi:10.1038/nrmicro2070 · Bergsbaken T, Fink SL, Cookson BT · Nat Rev Microbiol 2009 · review · Comprehensive mechanistic review of pyroptosis; covers caspase-1 pore formation, IL-1β/IL-18 processing, DAMPs release · archive status: failed (green OA, download attempted 2026-05-06; no downloadable URL found) no-fulltext-access ↩

6. doi:10.1016/j.tibs.2016.10.004 · He WT et al. · Trends Biochem Sci 2016 · review · “Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death”; covers GSDMD structure, disulfiram mechanism, MCC950 · not-oa ↩ ↩²

7. doi:10.1056/nejmoa1707914 · Ridker PM et al. (CANTOS trial) · N Engl J Med 2017 · rct · n=10,061 post-MI (randomized 1.5:1:1:1, placebo:50mg:150mg:300mg, s.c. q3mo) · Primary endpoint (nonfatal MI, nonfatal stroke, or cardiovascular death): 150-mg group HR 0.85, 95% CI 0.74–0.98, p=0.02075 (met pre-specified threshold p=0.02115); 300-mg group HR 0.86, 95% CI 0.75–0.99, p=0.031 (met threshold p=0.01058); 50-mg group HR 0.93, p=0.30 (ns) · All-cause mortality: HR 0.94, 95% CI 0.83–1.06, p=0.31 (ns) · Supports IL-1β axis as causal in atherosclerotic inflammation · local PDF available ↩